IP Library Granted Patent US 7,402,609
Granted Patent B2
US 7,402,609 · App. 11/079,996 · Granted Jul 22, 2008

Olopatadine formulations for topical administration

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,402,609
App. No.
11/079,996
Granted
Jul 22, 2008
Kind
B2
Abstract

Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the eye and nose are disclosed. The aqueous formulations contain approximately 0.17-0.62% (w/v) of olopatadine and an amount of polyvinylpyrrolidone or polystyrene sulfonic acid sufficient to enhance the physical stability of the formulations.

Claims (9)

1. A topically administrable solution composition for treating allergic or inflammatory disorders of the eye and nose, wherein the solution has a pH from 6.5-7.5 and a viscosity of 1-2 cps, and wherein the solution consists essentially of:

a) 0.18-0.22% (w/v) olopatadine;

b) 1.5-2% (w/v) polyvinylpyrrolidone having a weight average molecular weight of 50,000-60,000;

c) a preservative selected from the group consisting of benzalkonium chloride; benzododecinum bromide; and polyquaternium-1;

d) edetate disodium;

e) a tonicity-adjusting agent selected from the group consisting of mannitol and sodium chloride;

f) a buffering agent selected from the group consisting of phosphates and borates;

g) optionally a pH-adjusting agent selected from the group consisting of NaOH and HCl; and

h) water.

Assignments (3)
CONFIRMATORY DEED OF ASSIGNMENT EFFECTIVE APRIL 8, 2019 Recorded Dec 13, 2019
From: ALCON PHARMACEUTICALS LTD.
To: NOVARTIS AG
Reel/Frame 051285/0295 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2012
From: ALCON, INC.
To: ALCON PHARMACEUTICALS LTD.
Reel/Frame 028155/0624 →
MERGER Recorded May 31, 2011
From: ALCON, INC.
To: NOVARTIS AG
Reel/Frame 026376/0076 →